Reta

Informal abbreviation for retatrutide, the triple incretin receptor agonist (GLP-1/GIP/glucagon) under Phase 3 clinical investigation by Eli Lilly. Widely used in obesity research communities, online patient forums, and financial analyses to refer to the compound. Phase 2 trial data showing ~24% average weight loss over 48 weeks generated significant interest in "reta" as a potential successor to tirzepatide in the GLP-1-based weight loss drug pipeline.